[Expression and Clinical Prognostical Significance of RIP2 in Diffuse Large B Cell Lymphoma].

Xin-Chen Wang,K. Ding,Xiao-qiu Wang,Zhi-hua Wang,Jue Wang
DOI: https://doi.org/10.7534/j.issn.1009-2137.2018.01.028
2018-02-01
Abstract:OBJECTIVE To investigate the expression and prognosis significance of receptor interacting protein 2 (RIP2) in diffuse large B-cell lymphoma (DLBCL). METHODS The expression of RIP2 in DLBCL GCB and non-GCB type was detected by immunohistochemistry, at same time the expressions of BCL-2 and C-MYC were detected. Then, the role of RIP2 in development of DLBCL was analyzed by related clinical and pathological parameters. RESULTS The expression of RIP2 was related with middle-high risk group by IPI score, the An Arbor stage III+IV and intranodal lesions, and the differences were statistically significant (P<0.05). Besides, the single factor survival analysis suggested that GCB-type DLBCL showed a higher survival rate than that in non-GCB type(P<0.05). Patients with RIP2+ showed a lower survival rate as compared with patients with PIP2- (P<0.05), among which the patients receiving R-CHOP had a higher survival rate than that of those receiving CHOP (P<0.01). The expression of RIP2 in DLBCL cell lines was higher than that in peripheral mononuclear cells of normal subjects (P<0.01) and expressed differently in DLBCL of GCB and non-GCB type (P<0.01). CONCLUSION The expression of RIP2 may relate with the poor prognosis and specific subtype of DLBCL.
What problem does this paper attempt to address?